Status:
COMPLETED
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Hemodialysis Patients With Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
Eligibility Criteria
Inclusion
- Receiving stable maintenance hemodialysis 3 times a week.
- Dialysis patients with hyperphosphatemia
Exclusion
- Patients having history of a pronounced brain / cardiovascular disorder.
- Patients having severe gastrointestinal disorders.
- Patients having severe hepatic disorders.
Key Trial Info
Start Date :
March 18 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 4 2014
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT01833494
Start Date
March 18 2013
End Date
August 4 2014
Last Update
October 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JAPAN
Multiple Locations, Japan